DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 minute ago

MRNA·Moderna, Inc.

$.
-. (-.%)
After Hours
High
$78.48
Open
$76.64
Market Cap
27.18B
52W High
$85.60
Low
$67.31
P. Close
$68.27
P/E
-
52W Low
$22.28
Fwd P/E
-16.46
DailyIQ Est.
$41.83
Technical Score (1D)
73
BUY
News Sentiment
55
BULLISH
Profit‑taking after a 48% June rally and cautious analyst commentary triggered a sharp pullback in MRNA’s stock, signaling heightened risk aversion in the market. The decline is expected to persist over the next 1–10 trading days as traders digest the broader market correction and reassess the company’s valuation. Meanwhile, the FDA advisory panel’s unanimous 9‑0 vote keeps the mRNA‑1010 seasonal flu vaccine on track for an August 5 regulatory decision, which could lift sentiment if the outcome is favorable. The company’s long‑term growth prospects remain intact, with a target of cash breakeven by 2028 that supports a positive outlook for its pipeline. In the broader context, MRNA lagged 0.7% in the S&P 500 healthcare sector, which is range‑bound amid geopolitical tensions and AI stock volatility, underscoring a cautious environment for healthcare equities. The pullback, combined with sector weakness, may pressure valuation multiples, so traders should monitor any earnings guidance that could signal a shift in growth expectations. A favorable August 5 decision on mRNA‑1010 would likely provide a catalyst for a rebound, so watch the FDA announcement closely. Additionally, keep an eye on any regulatory updates or pipeline milestones that could alter the company’s cash‑breakeven timeline. Finally, observe market sentiment shifts in the healthcare sector, as changes there could amplify MRNA’s short‑term volatility.
Earnings Summary
Moderna, Inc. is a biotechnology firm headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) medicines and developing vaccines and therapeutics across respiratory, viral, bacterial, oncology, and rare disease areas, supported by partnerships with AstraZeneca, Merck, and Vertex; the company operates within the broader healthcare biotechnology sector. The most recent reported quarter, Q1 2026, showed earnings per share of –$1.18 versus an estimate of –$1.96, a beat, and revenue of $389 million, while the prior quarter, Q4 2025, recorded EPS of –$2.11 versus an estimate of –$2.18, also a beat, and revenue of $678 million; however, not enough information is available to compare the last two quarters with the prior two quarters in a comprehensive manner. Historically, Moderna’s revenue has fluctuated, peaking at $1.016 billion in Q3 2025 and falling to $389 million in Q1 2026, yet the company has consistently beaten EPS estimates in every quarter reported from Q1 2025 through Q1 2026, indicating a pattern of outperforming analyst expectations despite negative earnings. Recent analyst coverage has highlighted optimism: Morgan Stanley lifted its price target to $39 from $33, citing confidence in the vaccine pipeline and potential new product launches, while RBC Capital raised its target to $45, both suggesting expectations of future revenue growth tied to pipeline milestones; these upgrades underscore market sentiment that pipeline progress could translate into earnings improvement. Investors should watch for the Q2 2026 earnings release, paying particular attention to any guidance revisions, product launch announcements, and regulatory approvals, as these factors will likely be key drivers of revenue momentum and will influence whether the company continues its pattern of beating EPS estimates in the coming quarters.

EPS

EstBeatMiss
$-3.58$-2.71$-1.84$-0.98$-0.11Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$-2.00 - -
Q1'26$-1.96$-1.18+39.6%
Q4'25$-2.18$-2.11+3.4%
Q3'25$-2.18$-0.51+76.6%
Q2'25$-2.97$-2.13+28.3%
Q1'25$-3.18$-2.52+20.7%

Revenue

EstBeatMiss
$-46M$254M$554M$854M$1.2BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$104M - -
Q1'26$92M$389M+321.1%
Q4'25$254M$678M+167.1%
Q3'25 - $1.0B -
Q2'25 - $142M -
Q1'25 - $108M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

MRNA Stock Snapshot

MRNA is currently trading at $68.30, giving Moderna, Inc. a market cap of 27.18B. Today's range spans $67.31–$78.48, with shares opening at $76.64 and moving up $0.03 (0.0%) from the prior close. DailyIQ's technical score sits at 73/100 (BUY) with a news sentiment reading of 55/100.

Over the past year MRNA has traded between $22.28 and $85.60 - the current price is +206.6% off the 52-week low and -20.2% from the high. 31 analysts cover the stock with a Hold consensus and a mean 12-month target of $47.89 (range $22.00–$79.00), implying downside of -29.9%.

If you're looking for bullish momentum in Healthcare, MRNA is putting up the numbers: 73/100 technical score, BUY signal, neutral sentiment at 55/100. Price: $68.30 (in the upper portion of its 52-week range). The 27.18B market cap keeps it in play for institutional position sizes, and the $22.28–$85.60 annual range shows this stock can make real moves when it gets directional conviction behind it.

The combination of a BUY signal (73/100) and neutral news sentiment (55/100) puts MRNA on the screens of active managers who run quality-momentum overlays — a cohort that can build meaningful positions at 27.18B in Healthcare market cap without immediately moving the stock. At $68.30 (in the upper portion of its 52-week range in the $22.28–$85.60 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.